Issues in the early diagnosis of Parkinson's disease

Neurology

Volumn 49, Issue 1 SUPPL., 1997, Pages

  Koller, William C ^a   Montgomery, Erwin B ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALCOHOL; BUTYROPHENONE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARBON MONOXIDE; CHLORPROMAZINE; CYTARABINE; DILTIAZEM; HALOPERIDOL; LITHIUM; MANGANESE; METHYLDOPA; METOCLOPRAMIDE; NEUROLEPTIC AGENT; PHENOTHIAZINE DERIVATIVE; PHENYTOIN; PROCHLORPERAZINE; VALPROIC ACID; VERAPAMIL; VINCRISTINE;

ARTICLE; BRADYKINESIA; CLINICAL EXAMINATION; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; ESSENTIAL TREMOR; HUMAN; MOTOR DYSFUNCTION; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RIGIDITY; TREMOR;

EID: 0030806395     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.49.1_suppl_1.s10     Document Type: Article

References (161)

1. von Economo C. Encephalitis lethargica. Wien Klin Wochenschr 1917;30:581-585.
2. Finley KH. Postencephalitis manifestations of viral encephalitides. In: Fields WS, Blattner RJ, eds. Viral encephalitis: a symposium. Fifth annual scientific meeting of Houston Neurological Society. Springfield, IL: Thomas, 1958:69-94.
3. Klawans HL. Hemiparkinsonism as a late complication of hemiatrophy: a new syndrome. Neurology 1981;31:625-628.
4. Buchman AS, Goetz CG, Klawans HL. Hemiparkinsonism with hemiatrophy. Neurology 1988;38:527-530.
5. Mawdsley C, Ferguson FR. Neurological disease in boxers. Lancet 1963;2:795-801.
6. Guterman A, Smith RW. Neurological sequelae of boxing. Sports Med 1987;4:194-210.
7. Mena I, Marin O, Fuenzalida S, Cotzias GC. Chronic manganese poisoning. Clinical picture and manganese turnover. Neurology 1967;17:128-136.
8. Huang CC, Lu CS, Chu NS, et al. Progression after chronic manganese exposure. Neurology 1993;43:1479-1483.
9. Langston JW, Koller WC. Preclinical detection of Parkinson's disease. The next frontier: presymptomatic detection. Introduction. Neurology 1991;41(Suppl 2):5-7.
10. Koller WC, Langston JW, Hubble JP, et al. Does a long preclinical period occur in Parkinson's disease? Neurology 1991;41(Suppl 2):8-13.
11. Riederer P, Wuketich S. Time course of nigrostriatal degeneration in Parkinson's disease: a detailed study of influential factors in human brain amine analogues. J Neural Transm Park Dis Dement Sect 1976;38:277-301.
12. Hornykiewicz O. Parkinson's disease and its chemotherapy. Biochem Pharmacol 1975;24:1061-1065.
13. Forno LS, Alvord EC Jr. The pathology of parkinsonism. Part I: some observations and new correlations. Contemp Neurol 1971;8:119-130.
14. Scherman D, Desnos C, Darchen F, Javoy-Agid F, Agid Y. Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann Neurol 1989;26:551-557.
15. Fearnley JM, Lees A. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
16. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
17. Guttman M, Calne DB. In vivo characterization of cerebral dopamine systems in human parkinsonism. In: Jankovic J, Tolosa E, eds. Parkinson's disease and movement disorders. Baltimore: Urban and Schwarzenberg, 1988:49-58.
18. Forno LS, Alvord EC. Pathology of Parkinson's disease. In: Koller WC, ed. Handbook of Parkinson's disease. New York: Marcel Dekker 1987;209-236.
19. Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD. Glutathione-related enzymes in brain in Parkinson's disease. Ann Neurol 1994;36:356-361.
20. Poewe W, Gerstenbrand F, Ransmayr G, Plorer S. Premorbid personality of Parkinson patients. J Neural Transm Suppl 1983;19:215-224.
21. Santamaria J, Tolosa E, Valles A. Parkinson's disease with depression: a possible subgroups of idiopathic parkinsonism. Neurology 1986;36:1130-1133.
22. Hubble JP, Cao T, Hassanein RES, Neuberger JS, Koller WC. Risk factors in Parkinson's disease. Neurology 1993;43: 1693-1697.
23. Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 1988;38:1237-1244.
24. Calne DB, Langston JW, Martin WR, et al. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature 1985;317:246-248.
25. Snow BJ, Peppard RF, Guttman M, et al. Positron emission tomographic scanning demonstrates a presynaptic dopaminergic lesion in Lytico-Bodig. The amyotrophic lateral sclerosis-parkinsonism-dementia complex of Guam. Arch Neurol 1990;47:870-874.
26. Brooks DJ. Detection of preclinical Parkinson's disease with PET. Neurology 1991;41(Suppl 2):24-27.
27. Snow BJ, Martin WRW, Calne DB. A case of subclinical idiopathic parkinsonism detected with fluorodopa PET. Proceedings of the 10th International Symposium on Parkinson's Disease; 1991; Tokyo: 222.
28. Sawle GV, Wroe SJ, Lees AJ, Brooks DJ, Frackowiak RS. The identification of presymptomatic parkinsonism: clinical and [18F]dopa positron emission tomography studies in an Irish kindred. Ann Neurol 1992;32:609-617.
29. Morrish PK, Sawle GV, Brooks PJ. An [18F] dopa PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996;119:585-591.
30. Lee CS, Schulzer M, Mak E, et al. Clinical observations on the rate of progression of idiopathic parkinsonism. Brain 1994;117:501-507.
31. Ayd FJ. A survey of drug-induced extrapyramidal reactions. JAMA 1961;175:1054-1060.
32. Goetz CG. Drug-induced parkinsonism and idiopathic Parkinson's disease [letter]. Arch Neurol 1983;40:325-326.
33. Sage JI, Mark MH. Diagnosis and treatment of Parkinson's disease in the elderly. J Gen Intern Med 1994;9:583-589.
34. Stephen PJ, Williamson J. Drug-induced parkinsonism in the elderly. Lancet 1984;2:1082-1083.
35. Marti Masso JF, Carrera N, Urtasun M. Drugs inducing parkinsonism in our environment [letter]. J Neurol Neurosurg Psychiatry 1991;54:1025.
36. Burn DJ, Brooks DJ. Nigral dysfunction in drug-induced parkinsonism. An 18F-dopa study. Neurology 1993;43:552-556.
37. Rajput AH, Rozdilsky B, Kornykiewicz O, Shannack K, Lee T, Seeman P. Reversible drug-induced parkinsonism: clinicopathologic study of two cases. Arch Neurol 1982;39:644-646.
38. Bocola V, Fabbrini G, Sollecito A, Paladini C, Martucci W. Neuroleptic-induced parkinsonism: MRI findings in relation to clinical course after withdrawal of neuroleptic drugs. J Neurol Neurosurg Psychiatry 1996;60:213-216.
39. Lees AJ. When did Ray Kennedy's Parkinson's disease begin? Mov Disord 1992;7:110-116.
40. Tetrud JW. Preclinical Parkinson's disease: detection of motor and non-motor manifestations. Neurology 1991;41(Suppl 2):69-72.
41. Watts RL, Mandir AS, Ahn KJ, Juncos JL, Zakers GO, Freeman A. Electrophysiologic analysis of early Parkinson's disease. Neurology 1991;41(Suppl 2):44-48.
42. Doty RL, Golbe LI, McKeown DA, Stern MB, Lerach CM, Crawford D. Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson's disease. Neurology 1993;43:962-965.
43. Wasson JH, Sox HC, Neff RK, Goldman L. Clinical prediction rules: applications and methodological standards. N Engl J Med 1985;313:793-799.
44. Montgomery EB Jr, Buchholz SR. The striatum and motor cortex in motor initiation and execution. Brain Res 1991;549: 222-229.
45. Montgomery EB Jr, Nuessen J. The movement speed/accuracy operator in Parkinson's disease. Neurology 1990;40: 269-274.
46. Patrick HT, Levy DM. Parkinson's disease: a clinical study of 146 cases. Arch Neurol 1922;7:711-720.
47. Ward CD, Hess WA, Calne DB. Olfactory impairment in Parkinson's disease. Neurology 1983;33:943-946.
48. Doty RL, Newhouse MG, Azalina JD. Internal consistency and short-term test re-test reliability of the University of Pennsylvania Smell Identification Test. Chem Senses 1985; 33:943-946.
49. Quinn NP, Rossor MN, Marsden CD. Olfactory threshold in Parkinson's disease. J Neurol Neurosurg Psychiatry 1987;50: 88-90.
50. Doty RL, Perl DP, Steele JC, et al. Olfactory dysfunction in three neurodegenerative diseases. Geriatrics 1991;46(Suppl 1):47-51.
51. Celesia GG, Wanamaker WM. Psychiatric disturbances in Parkinson's disease. Dis Nerv Sys 1972;33:577-583.
52. Gotham AM, Brown RG, Marsden CD. Depression in Parkinson's disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 1986;49:381-389.
53. Brown GL, Wilson WP. Parkinsonism and depression. South Med J 1972;65:540-545.
54. Mayeux R, Stern Y, Rosen J, Leventhal J. Depression, intellectual impairment and Parkinson's disease. Neurology 1981; 31:645-650.
55. Mayeux R, Williams JB, Stern Y, Cote L. Depression and Parkinson's disease. Adv Neurol 1984;40:241-250.
56. de Rijk MC, Breteler MM, Graveland GA, et al. Prevalence of Parkinson's disease in the elderly: the Rotterdam study. Neurology 1995;45:2143-2146.
57. Snow B, Wiens M, Hertzman C, Calne D. A community survey of Parkinson's disease. Can Med Assoc J 1989;141:418-422.
58. Schoenberg BS, Anderson DW, Haerer AF. Prevalence of Parkinson's disease in the biracial population of Copiah County, Mississippi. Neurology 1985;35:841-845.
59. Morgante L, Rocca WA, Di Rosa AE, et al. Prevalence of Parkinson's disease and other types of parkinsonism: a door-to-door survey in three Sicilian municipalities. The Sicilian neuro-epidemiologic study. Neurology 1992;41:1901-1907.
60. Marttila RJ, Rinne UK. Epidemiology of Parkinson's disease in Finland. Acta Neurol Scand 1976;53:81-102.
61. Koller WC. The diagnosis of Parkinson's disease. Arch Intern Med 1984;144:2146-2147.
62. Cleeves L, Findley LJ, Koller W. Lack of association between essential tremor and Parkinson's disease. Ann Neurol 1988; 24:23-26.
63. Geraghty JJ, Jankovic J, Zetusky WJ. Association between essential tremor and Parkinson's disease. Ann Neurol 1985; 17:329-333.
64. Koller WC, Rubino FA. Combined resting-postural tremor. A subclass of essential tremor. Arch Neurol 1985;42:683-685.
65. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism: a prospective study. Can J Neurol Sci 1991;18:275-278.
66. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of the clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
67. Koller WC. How accurately can Parkinson's disease be diagnosed. Neurology 1992;42(Suppl 1):6-16.
68. Koller WC, Hubble JP. Classification of parkinsonism. In: Koller WC, ed. Handbook of Parkinson's disease. New York: Marcel Dekker, 1992:59-104.
69. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy: a heterogenous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia, and dementia. Arch Neurol 1964;10:333-359.
70. Litvan I, Agid Y, eds. Progressive supranuclear palsy. Clinical and research approaches. New York: Oxford University Press, 1992.
71. Golbe LI, David PH, Schoenberg BS, Duvoisin RC. Prevalence and natural history of progressive supranuclear palsy. Neurology 1988;38:1031-1034.
72. Maher ER, Lees AJ. The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1986;36:1005-1008.
73. Golbe LI. Progressive supranuclear palsy. In: Stern M, Koller WC, eds. Parkinsonian syndromes. New York:Marcel Dekker, 1993:224-248.
74. Litvan I, Mangone CA, McKee A, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathologic study. J Neurol Neurosurg Psychiatry 1996; 60:615-620.
75. Mascucci EF, Kurtzke JF. Tremor in progressive supranuclear palsy. Acta Neurol Scand 1989;80:296-300.
76. Tolosa E, Valldeoriola F, Marti MJ. Clinical diagnosis and diagnostic criteria of progressive supranuclear palsy (Steele- Richardson-Olszewski syndrome). J Neurol Transm Suppl 1994;42:15-31.
77. Daniel SE, de Bruin VM, Lees AJ. The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): a reappraisal. Brain 1995;118:759-770.
78. Jackson JA, Jankovic J, Ford J. Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Ann Neurol 1983;13:273-278.
79. Saitoh H, Yoshii F, Shinohara Y. Computed tomographic findings in progressive supranuclear palsy. Neuroradiology 1987;29:168-171.
80. Hauw JJ, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994; 44:2015-2019.
81. Litvan I, Hauw J-J, Bartko JJ, et al. Validity and reliability of the preliminary neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 1996;55:97-105.
82. Lantos PL. The neuropathology of progressive supranuclear palsy. J Neural Transm Suppl 1994;42:137-152.
83. Dubinsky RM, Jankovic J. Progressive supranuclear palsy and a multi-infarct state. Neurology 1987;37:570-576.
84. Fearnley JM, Revesz T, Brooks DJ, Frackowiak RS, Lees AJ. Diffuse Lewy body disease presenting with a supranuclear gaze palsy. J Neurol Neurosurg Psychiatry 1991;54:159-161.
85. Foster NL, Gilman S, Berent S, et al. Progressive subcortical gliosis and progressive supranuclear palsy can have similar clinical and PET abnormalities. J Neurol Neurosurg Psychiatry 1992;55:707-713.
86. Lees AJ. The Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). In: Marsden CD, Fahn S, eds. Movement disorders 2. London: Butterworth, 1987:272-287.
87. Blin J, Baron JC, Dubois B, et al. Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations. Arch Neurol 1990;47:747-752.
88. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSD International Workshop. Neurology 1996;47:1-9.
89. Litvan I, Agid Y, Jankovic J, et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology 1996;46:922-930.
90. Wenning GK, Ben-Shlomo Y, Magalhaels M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy: an analysis of 100 cases. Brain 1994;117-835-845.
91. Albanese A, Colosimo C, Bentivoglio AR, et al. Multiple system atrophy presenting as parkinsonism: clinical features and diagnostic criteria. J Neurol Neurosurg Psychiatry 1995; 59:144-151.
92. Quinn N. Multiple system atrophy: the nature of the beast. J Neurol Neurosurg Psychiatry 1989;52(Suppl):78-89.
93. Fearnley JM, Lees AJ. Striatonigral degeneration: a clinicopathologic study. Brain 1990;113:1823-1842.
94. Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 1969;32:28-34.
95. Wenning GK, Ben-Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinicopathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry 1995;58: 160-166.
96. Colosimo C, Albanese A, Hughes DJ, de Bruin VM, Lees AJ. Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease. Arch Neurol 1995;52:294-298.
97. Wenning GK, Tison F, Elliott L, Quinn NP, Daniel SE. Olivopontocerebellar pathology in multiple system atrophy. Mov Disord 1996;11:157-162.
98. Nakazato Y, Yamazaki H, Hirato J, Ishida Y, Yamaguchi H. Oligodendroglial microtubular tangles in olivopontocerebellar atrophy. J Neuropathol Exp Neurol 1990;49:521-530.
99. Mochizuki A, Mizusawa H, Ohkoshi N, et al. Argentophilic intracytoplasmic inclusions in multiple system atrophy. J Neurol 1992;239:311-316.
100. Lantos PL, Papp MI. Cellular pathology of multiple system atrophy: a review [editorial]. J Neurol Neurosurg Psychiatry 1994;57:129-133.
101. Daniel SE, Geddes JF, Revesz T. Glial cytoplasmic inclusions are not exclusive to multiple system atrophy [letter]. J Neurol Neurosurg Psychiatry 1995;58:262.
102. Quinn N. Multiple system atrophy. In: Marsden CD, Fahn S, eds. Movement disorders 3. London: Butterworth-Heinemann, 1994:262-281.
103. Riley DE, Lang AE, Lewis A, et al. Cortical-basal ganglionic degeneration. Neurology 1990;40:1203-1212.
104. Riley DE, Lang AE. Cortical basal ganglionic degeneration. In: Stern M, Koller WC, eds. Parkinsonian syndromes. New York: Marcel Dekker, 1993:379-392.
105. Rinne JO, Lee MS, Thompson PD, Marsden CD. Corticobasal degeneration. A clinical study of 36 cases. Brain 1994;117-1183-1196.
106. Watts RL, Mirra SS, Richardson EP Jr. Corticobasal degeneration. In: Marsden CD, Fahn S, eds. Movement disorders 3. London: Butterworth-Heinemann, 1994:282-299.
107. Rebeiz JJ, Kolodny EH, Richardson EP. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 1968;18:20-23.
108. Gibb WR, Luthert PJ, Marsden CD. Corticobasal degeneration. Brain 1989;112:1171-1192.
109. Sudarsky L. Geriatrics. Gait disorder in the elderly. N Engl J Med 1990;322:1441-1446.
110. Critchley M. Arteriosclerotic parkinsonism. Brain 1929;52: 23-83.
111. Koller WC, Glatt SL, Fox JH. Senile gait: a distinct neurologic entity. Clin Geriatr Med 1985;1:661-669.
112. FitzGerald PM, Jankovic J. Lower body parkinsonism: evidence for a vascular etiology. Mov Disord 1989;4:249-253.
113. Nutt JG, Marsden CD, Thompson PD. Human walking and higher-level gait disorders, particularly in the elderly. Neurology 1993;43:268-279.
114. Bennett DA, Beckett LA, Murray AM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996;334:71-76.
115. Marttila RJ. Epidemiology. In: Koller WC, ed. Handbook of Parkinson's disease, 2nd ed. New York: Marcel Dekker, 1992:35-57.
116. Dubois B, Boller F, Pillon B, Agid Y. Cognitive deficits in Parkinson's disease. In: Boller F, Grafman J, eds. Handbook of neuropsychology. Amsterdam: Elsevier Science, 1991:195-240.
117. Marder K, Mayeux R. The epidemiology of dementia in patients with Parkinson's disease. Adv Exp Med Biol 1991;295: 439-445.
118. Mayeux R, Chen J, Mirabėllo E, et al. An estimate of the incidence of dementia in idiopathic Parkinson's disease. Neurology 1990;40:1513-1517.
119. Ebmeier KP, Calder SA, Crawford JR, Steward L, Besson JA, Mutch WJ. Clinical features predicting dementia in idiopathic Parkinson's disease: a follow-up study. Neurology 1990;40:1222-1224.
120. Mayeux R, Denaro J, Hemenegildo N, et al. A population-based investigation of Parkinson's disease with and without dementia: relationship to age and gender. Arch Neurol 1992; 49:492-497.
121. Biggins CA, Boyd JL, Harrop FM, et al. A controlled, longitudinal study of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 1992;55:566-571.
122. Glatt SL, Hubble JP, Lyons K, et al. Risk factors for dementia in Parkinson's disease: effect of education. Neuroepidemiology 1996;15:20-25.
123. Marder K, Tang MX, Cote L, Stern Y, Mayeux R. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol 1995;52:695-701.
124. Caparros-Lefebvre D, Pecheux N, Petit V, Duhamel A, Petit H. Which factors predict cognitive decline in Parkinson's disease? J Neurol Neurosurg Psychiatry 1995;58:51-55.
125. Boller F, Mizutani T, Roessmann U, Gambetti P. Parkinson disease, dementia, and Alzheimer disease: clinicopathological correlations. Ann Neurol 1980;7:329-335.
126. Jellinger K. Alzheimer pathology in Parkinson's disease [letter]. Neurology 1989;39:874-875.
127. Rinne JO, Rummukainen J, Paljarvi L, Rinne UK. Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 1989;26:47-50.
128. Chui HC, Teng EL, Henderson VW, Moy AC. Clinical subtypes of dementia of the Alzheimer type. Neurology 1985;35: 1544-1550.
129. Mayeux R, Stern Y, Spanton S. Heterogeneity in dementia of the Alzheimer type: evidence of subgroups. Neurology 1985; 35:453-461.
130. Stern Y, Mayeux R, Sano M, Hauser WA, Bush T. Predictors of disease course in patients with probable Alzheimer's disease. Neurology 1987;37:1649-1653.
131. Stern Y, Hesdorffer D, Sano M, Mayeux R. Measurement and prediction of functional capacity in Alzheimer's disease. Neurology 1990;40:8-14.
132. Soininen H, Laulumaa V, Helkala EL, Hartikainen P, Riekkinen PJ. Extrapyramidal signs in Alzheimer's disease: a 3-year follow-up study. J Neural Transm Park Dis Dement 1992;4:107-119.
133. Mohr E, Litvan I, Williams J, Fedio P, Chase TN. Selective deficits in Alzheimer and parkinsonian dementia: visuospatial function. Can J Neurol Sci 1990;17:292-297.
134. Huber SJ, Christy JA, Paulson GW. Cognitive heterogeneity associated with clinical subtypes of Parkinson's disease. NNBN 1991;4:147-157.
135. Tröster AI, Paolo AM, Lyons KE, Glatt SL, Hubble JP, Koller WC. The influence of depression on cognition in Parkinson's disease: a pattern of impairment distinguishable from Alzheimer's disease. Neurology 1995;45:672-676.
136. Burkhardt CR, Filley CM, Kleinschmidt-DeMasters BK, de la Monte S, Norenberg MD, Schneck SA. Diffuse Lewy body disease and progressive dementia. Neurology 1988;38:1520-1528.
137. Byrne EJ, Lennox G, Lowe J, Godwin-Austen RB. Diffuse Lewy Body disease: clinical features in 15 cases. J Neurol Neurosurg Psychiatry 1989;52:709-717.
138. Crystal HA, Dickson DW, Lizardi JE, Davies P, Wolfson LI. Antemortem diagnosis of diffuse Lewy body disease. Neurology 1990;40:1523-1528.
139. Hansen LA, Masliah E, Galasko D, Terry RD. Plaque-only Alzheimer disease is usually the Lewy body variant, and vice versa. J Neuropathol Exp Neurol 1993;52:648-654.
140. Lippa CF, Smith TW, Swearer JM. Alzheimer's disease and Lewy body disease: a comparative clinicopathological study. Ann Neurol 1994;35:81-88.
141. Perry RH, Irving D, Blessed G, Fairbairn A, Perry EK. Senile dementia of Lewy body type: a clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 1990;95:119-139.
142. Katzman R, Galasko D, Saito T, Thal LJ, Hansen L. Genetic evidence that the Lewy body variant is indeed a phenotypic variant of Alzheimer's disease. Brain Cognition 1995;28: 259-265.
143. Gibb WR, Esiri MM, Lees AJ. Clinical and pathological features of diffuse cortical Lewy body disease (Lewy body dementia). Brain 1987;110:1131-1153.
144. Kosaka K, Yoshimura M, Ikeda K, Budka H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree - new disease? Clin Neuropathol 1984;3:185-192.
145. Filley CM. Neuropsychiatrie features of Lewy body disease. Brain Cogn 1995;28:229-239.
146. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. Br Med J 1992;305:673-678.
147. Wszolek ZK, Pfeiffer RF, Bhatt MH, et al. Rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration. Ann Neurol 1992;32:312-320.
148. Jankovic J, Kirkpatrick JB, Blomquist KA, Langlais PJ, Bird ED. Late-onset Hallervorden-Spatz disease presenting as familial parkinsonism. Neurology 1985;35:227-234.
149. Will RG, Lees AJ, Gibb W, Barnard RO. A case of progressive subcortical gliosis presenting clinically as Steele-Richardson-Olszewski syndrome. J Neurol Neurosurg Psychiatry 1988;51:1224-1227.
150. Farlow MR, Yee RD, Dlouhy SR, Conneally PM, Azzarelli B, Ghetti B. Gerstmann-Straussler-Scheinker disease. I: Extending the clinical spectrum. Neurology 1989;39:1446-1452.
151. McKeith IG, Perry RH, Fairbairn AF, Jabeen S, Perry EK. Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med 1992;29:911-922.
152. McKeith IG, Fairbairn AF, Bothwell RA, et al. An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type. Neurology 1994;44:872-877.
153. Sage JI, Mark MH. Diffuse Lewy body disease. In: Stern M, Koller WC, eds. Parkinsonian syndromes. New York: Marcel Dekker, 1993:393-411.
154. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB). Neurology 1996;47:1113-1124.
155. Gibb WR. The neuropathology of Parkinson's disease. In: Jankovic J, Tolosa E, eds. Parkinson's disease and movement disorders. Baltimore: Urban and Schwarzenberg, 1988:205-223.
156. Ward CD, Gibb WR. Research diagnostic criteria for Parkinson's disease. Adv Neurol 1990;53:245-249.
157. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol 1992;32(Suppl):125-127.
158. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease? Neurology 1992;42:1142-1146.
159. Murrow RV, Schweiger GD, Kepes JJ, Koller WC. Parkinsonism due to basal ganglia lacunar state: clinicopathologic correlation. Neurology 1990;40:897-900.
160. Sage JI, Miller DC, Golbe LI, Walters A, Duvoisin RC. Clinically atypical expression of pathologically typical Lewy body parkinsonism. Clin Neuropharmacol 1990;13:36-47.
161. Joachim CL, Morris JH, Sekloe DJ. Clinically diagnosed Alzheimer's disease: autospy results in 150 cases. Ann Neurol 1988;24:50-56.